Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 16/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730991 | 0.88 | PTGS2 (0.52) | — | |
| SCHEMBL602787 | 0.84 | HRH4 (0.62) | HRH4 | |
| SCHEMBL6141621 | 0.83 | HRH4 (0.57) | HRH4GAAPARP1DRD2DRD3 | |
| SCHEMBL6141648 | 0.82 | CHRNA7 (0.51) | HRH4GAAKMT2ADRD2DRD3 | |
| SCHEMBL14125524 | 0.82 | MCL1 (0.43) | — | |
| SCHEMBL6141992 | 0.82 | HRH4 (0.59) | HRH4 | |
| SCHEMBL6141955 | 0.81 | GAA (0.53) | HRH4GAAPARP1DRD2DRD3 | |
| SCHEMBL6141941 | 0.81 | HRH4 (0.50) | HRH4GAAPARP1DRD2DRD3 | |
| SCHEMBL18092620 | 0.81 | KDM4E (0.58) | HRH4GAAPARP1 | |
| SCHEMBL6141995 | 0.78 | GAA (0.50) | HRH4GAAPARP1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-1694703-A | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | disclosed |
| EP-1551406-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085487-A1 | Heterocyclic compounds | CARRUTHERS NICHOLAS I (US) | 2005-04-21 | — | — | US | disclosed |
| US-6803362-B2 | ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2004-10-12 | — | — | US | disclosed |
| WO-2004022061-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030207893-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085487-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | HRH4 1501/4885GAA 817/4885PARP1 300/4885 |
| US-20030207893-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | HRH4 1508/4885GAA 816/4885PARP1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.